All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (anti PD-1) as a Monotherapy or Combination Therapy with AGEN1884 (anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer (Second Line) - RaPiDS
Structural and Functional Connectivity Changes in the Brain in Response to Diagnostic Nerve Blocks in Stroke Survivors
Identify changes in brain functional connectivity associated with diagnostic nerve blocks (DNB) to relieve spasticity in stroke survivors.
Primary Investigator: John McGuire, MD
Status: Currently Enrolling
IPSEN Abolish: Study to Assess the Effectiveness of AboBoNT-A Injections for Adult Lower Limb Spasticity in a Real Life Cohort (AboLiSh)
Observational study to assess the longitudinal attainment of person centered and function related goals after one or more abobotulinum toxin A (aboBoNT-A) injections in the lower limb using the cumulated Goal Attainment Scaling -Leg (GASleg) T score in a real life clinical setting.
Primary Investigator: Nicholas Ketchum, MD
Status: Currently Enrolling
Merz: Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke (PLUS)
To test the safety and efficacy of NT 201 (Xeomin) for treating lower limb spasticity caused by stroke or traumatic brain injury in adult subjects, followed by an open label extension with or without combined upper limb treatment
Primary Investigator: Nicholas Ketchum, MD
Status: Currently Enrolling
SleepSmart: The Sleep for Stroke Management and Recovery Trial
Designed to evaluate ischemic stroke patients or patients with transient ischemic attack (TIA) for obstructive sleep apnea. Patients who qualify, will help assess whether continuous positive airway pressure (CPAP) for obstructive sleep apnea, after stroke, helps with recovery or helps prevent another stroke.
Status: Currently enrolling
ARCADIA: Atrial Cardiopathy and Antithrombotic Drugs in Prevention after Cryptogenic Stroke
A randomized, controlled trial of anticoagulation with Apixaban versus Aspirin for patients with embolic stroke of undetermined source, or ESUS, and evidence of atrial cardiopathy.
Status: Currently enrolling
A Phase 1, Dose Escalation and Expansion Study of Engineered Donor Grafts Derived from Mobilized Peripheral Blood (Orcagraft) With Single Agent Graft-Versus-Host Disease Prophylaxis, In Recipients Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies
A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase II Clinical Trial of GVAX Pancreas Vaccine (with Cyclophosphamide) in Combination with Nivolumab and Stereotactic Body Radiation Therapy (SBRT) Followed by Definitive Resection for Patients with Borderline Resectable Pancreatic Adenocarcinoma
Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC)
Adaptive Modification of Neoadjuvant Therapy Based on Clinical Response in Patients with Localized Pancreatic Cancer
Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma MASTER TRIAL
Genomically-Guided Treatment Trial in Brain Metastases
PD-Inhibitor (Nivolumab) and Ipilimumab followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
advanced kidney cancer, by adding a drug called cabozantinib to another treatment after
receiving the standard treatment?
A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation
Evaluation of Hemodynamic Parameters Following Transjugular Intrahepatic Portosystemic Shunt (TIPS)
During a TIPS procedure, a shunt or stent (mesh tube) is passed down the jugular vein (the vein above the collarbone in the neck) using fluoroscopy (real time x-rays) guidance. The stent then is inserted between the portal vein (vein that carries blood from the intestines into the liver) to a hepatic vein (vein that carries blood away from the liver back to the heart). This means that blood that would usually go to the intestinal veins is now going to the heart. Because more blood will be flowing to the heart, the heart needs to be strong enough to handle the extra volume.
This study is being